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Abstract: The interaction of carbonic anhydrase (CA) isozymes I and II with a series of As(III) derivatives,
dialkyl and diaryl rac-2,3-dimyristoyloxypropyldithioarsonites, was investigated kinetically and
spectrophotometrically, utilizing the native and Co(II)-substituted enzymes. Depending on the substitution
pattern at the -As(SR)2 moiety of the investigated derivatives, inactive compounds were found for R phenyl
or naphthyl, and active ones for derivatives containing carboxyl groups (R CH2COOH, cysteinyl and
glutathionyl). Together with the arsonolipids previously investigated, the active compounds of this series
the "lipothioarsenites"- constitute a novel class of CA inhibitors that bind to the metal ion within the
enzyme active site, as proved by changes in the electronic spectra of adducts of such inhibitors with
Co(II)CA.
Introduction
Inhibition of the zinc enzyme carbonic anhydrase (CA, EC 4.2.1.1) with sulfonamide
2’3 or inorganic
complexing anions
3’4 was extensively studied for at least two reasons: the first type of inhibitors led to the
development of several valuable clinical drugs, used in the treatment or prevention of glaucoma, gastric
/i ulcers, mountain sickness or epilepsia among others, whereas the second major class of inhibitors, the
anions, allowed the discovery of mechanisms by which inhibition (and also catalysis) occur.
9"11 Besides these
two classes of compounds, inhibition was also reported by aniline,
9 phenol,
12 thiophenols and heterocyclic
mercaptans
315 as well as for some P(V)
6 and As(V) derivatives.
7
Organic inhibitors from diverse classes possess a coordinating functional group (such as
SH, OH, NH=, AsO3H2) generally attached to a bulky structural element (such as an aromatic/heterocyclic
ring, possibly substituted with several side chains, but also aliphatic moieties are effective, for example
perfluoroalkyl in the case of sulfonamides,
8 or dihydroxypropyl for arsonic acids7). Both these elements are
extremely important for inhibition, as the first moiety generally interacts directly with the metal center or the
solvent molecule bound to the metal ion,
2’3’9’9"22 whereas the second one assures stability to the enzyme-
inhibitor adduct by means of cooperative interactions with amino acid side chains lining the active site. This
was well illustrated in the case of the sulfonamide inhibitors, by the report of the X-ray crystallographic
20.21 structures of several adducts of isozymes CA I -III with such inhibitors, by Liljas group.
Taking into account our interest in both sulfonamide as well as non-sulfonamide inhibitors of these
enzymes
23,24 which might lead to the development of novel therapeutical approaches (such as the design of
specific NMR imaging contrast agents25, specific antiulcer drugs,26-etc) we recently investigated a large series
of compounds for their effect upon these enzymes. Interesting activity was discovered for some organo-
26 16.27 17 element derivatives containing Ge(IV), P(V) or As(V) Here we report the extension of such studies on
As(III) derivatives, more precisely, the interaction of thioarsenites with isozymes I and II of CA.
Mention should be made that thioarsenites of the trype RAs(SR’)2 were of pharmacological interest
as antiparasite agents,
TM since the nature of the R’ moieties (present in the thiol from which they were
prepared) could impart favorable solubility characteristics to them as well as to their metabolites, the
biologically active arsenoso compounds ("RAsO").
28b
# See ref.
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Melting points were determined with a heating plate microscope and are not corrected; IR spectra
were obtained in KBr pellets with a Perkin-Elmer 16PC FTIR spectrometer, whereas H-NMR spectra with a
Varian T-60 or Bruker CPX200 apparatus in solvents specified in each case. Chemical shifts are expressed as
5 values relative to MenSi as internal standard. Some signals in the NMR spectra appear as broad singlets
probably due to aggregation of the long chain lipid-like derivatives 1. Optical rotations were measured on a
Schmidt & Haensch Polatronic universal polarimeter using a 5 cm cell. Thin layer chromatography (tic) was
done using silicagel H from Merck. Visualisation was effected by spraying the microslides with 35% H2SO4
and charring. Elemental analysis were done by microcombustion with a Carlo Erba automated analyzer.
The As(III) derivatives 1 were prepared from rac-2,3-dimyristoyloxypropyl-arsonic acid and the
corresponding thiols in acetone or DMSO as solvents, as described below. Buffers, 4-nitrophenyl acetate,
acetonitrile, cysteine hydrochloride, mercaptoacetic acid, glutathione and inorganic reagents were from Sigma
or Aldrich; 2-naphthalenethiol was from Merck and were used without additional purification.
Human CA I and CA II cDNAs were expressed in Ion Escherichia coli strain SG20043 from the
plasmids described by Forsman et al.
29 (the two plasmids were a gift from Prof. Sven Lindskog, Umea
30 University, Sweden). Cell growth conditions were those described by Lindskog s group, and enzymes were
purified by affinity chromatography according to the method of Khalifah et al.
1 Enzyme concentrations were
determined spectrophotometrically at 280 nm, utilizing a molar absorptivity of 49 mM.cm
l for CA I and 54
mMJ.cm for CA II, respectively, based on Mr= 28.85 kDa for CA I, and 29.3 kDa for CA II,
respectively.32,
33 Apoenzymes were prepared by dialysing the zinc enzymes against 50 mM pyridine-2,6-
dicarboxylic acid (Sigma) in 0.2 M phosphate buffer at 4C for 2 hours,x4 The chelating agent was removed
by dialysis against 20 mM Tris-H2SO4 (pH 7.5) and then 1.1 equivalents of COSO4 were added to the
apoenzymes in order to obtain Co(II)CAs.
Electronic spectra were recorded with a Cary 3 spectrophotometer interfaced with an IBM PC. Initial
rates of 4-nitrophenyl acetate hydrolysis were monitored spectrophotometrically, at 400 nm and 25C, with a
Cary 3 apparatus interfaced with an IBM compatible PC. Solutions of substrate were prepared in anhydrous
acetonitrile; the substrate concentrations varied between 10
.2 and 10
4 M. A molar absorption coefficient e
18400 M.cm
j was used for the 4-nitrophenolate formed by hydrolysis, in the conditions of the experiments
(pH 7.80), as reported by Pocker and Stone.
35 Non-enzymatic hydrolysis rates were always subtracted from
the observed rates. Stock solutions of inhibitors (10 mM) were prepared in DMSO and dilutions up to 0.1
ktM were done with distilled deionized water. Duplicate experiments were done for each inhibitor, and the
values reported throughout the paper are the averages of such results. ICs0 values represent the molarity of
inhibitor producing a 50% decrease of enzyme specific activity for the investigated reaction.
General procedure for the preparation of compounds of type 1
rac-2,3-Dimyristoylarsonic acid and the corresponding mercaptoderivative (thiophenol, 2-naphthalenethiol,
mercaptoacetic acid, cysteine and glutathione, respectively) in a molar ratio of 1:4, were stirred in acetone (for
the first three mercaptoderivatives) or DMSO (for the last two) at 50-55C for 20-150 min, and then at room
temperature for an additional 1.5-2 hours. TLC showed the reaction to be completed after approximately 60
min. The solution of ld was left overnight at-20C and the obtained precipitate was centrifuged. When no
precipitation occurred (le), the acetone was evaporated in vacuo and the obtained solid recrystallized from
petroleum ether. Compound la was precipitated by adding water to its concentrated acetone solution. When
the reactions were carried out in DMSO, the desired product was precipitated by addition of chloroform and
petroleum ether (for lb) or water (for lc). Yields were in the range of 54-96%.
Dicarboxymethyl rac-2,3-dimyristoyloxypropyldithioarsonite la: white amorphous solid, m.p. 33 35 C
(from acetone); yield 96 %. IR (KBr), cm- 3418 br (w); 2918 (s); 2850 (s); 1743 (vs); 1707 (vs); 1470 (m);
1304 (m); 1204 (s); 1164 (s). H-NMR (CC14) , ppm: 0.90 (br s,6H, 2Me); 1.10-1.28 (m, 44H, 22CH2);
2.20 (br s, 6H, CH2As + 2CH2COO from myristoyl); 3.60 (s,4H, 2SCH2); 4.20 (m,2H, COOCH2); 5.40
(m, lH, COOCH). Rf 0.95 in CHC13/AcOH 10:1, v/v. Analysis, found: C, 55.5; H, 8.7; S, 8.4 %;
C35H6508AsS requires: C, 55.8; H, 8.6; S, 8.5%.
Dicysteinyl-rac-2,3-dimyristoyloxypropyldithioarsonite dihydrochloride lb: white solid, m.p. 212C (dec.);
yield 73%. IR (KBr), cm: 2922 (vs); 2852 (vs); 1742 (s); 1584 (vs); 1490 (vs); 1410 (s); 1340 (s); 1298
(s); 848 (s); 540 (s). tH-NMR (DMSO-d6), 5, ppm: 0.95 (br s,6H, 2Me); 1.15-1.29 (m, 44H, 22CH2); 2.20
(br s, 6H, CH2As + 2CH2COO from myristoyl); 3.72 (s,4H, 2SCH2); 3.97 (m, 2H, 2 CH from the cysteinyl
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moieties); 4.15 (m,2H, COOCH2); 5.42 (m, lH, COOCH from the myristoyloxypropyl moiety). Rt-0.62 in
CHC13/MeOH/concentrated NH 4:2:1, v/v. Analysis, found: C, 50.0; H, 8.3; N, 2.8; S, 7.3 %;
C37HTN2OsAsS2 2HC1 requires: C, 50.2; H, 8.2; N, 3.1; S, 7.2%.
Diglutathionyl rac-2,3-dimyristoyloxypropyldithioarsonite lc" white solid, m.p. 180 C (dec.); yield 91%.
IR (KBr), cm-: 3271 br (m); 2922 (s); 2852 (m); 1740 (m); 1650 (m); 1536 (m); 1414 (w); 1230 br (w). H-
NMR (DMSO-d6), 5, ppm: 0.95 (br s,6H, 2Me); 1.16-1.28 (m, 44H, 22CH2); 2.24 (br s, 6H, CH2As +
2CH2COO from myristoyl); 2.56 (m, 4H, 2COCH2 from the glutamoyl moiety of glutatione); 2.78 (s, 4H,
2CH2COO from the glycyl moiety of glutathione); 3.78 (s,4H, 2SCH2); 3.83 (m, 2H, 2CHNHCO from the
cysteinyl moiety of glutathione) 3.92 (m, 2H, 2 CH from the glutamoyl moiety of glutatione); 4.14 (m,2H,
COOCH2); 5.44 (m,lH, COOCH from the myristoyloxypropyl moiety). Re 0.00 in CHCI.a/AcOH 10:1, v/v;
[]D -13.3 (in chloroform, c 0.15). Analysis, found: C, 50.8; H, 7.3; N, 7.0; S, 5.3 %;
C49H87N6016AsS2requires: C, 50.9; H, 7.5; N, 7.2; S, 5.5%.
Diphenyl rac-2,3-dimyristoyloxypropyldithioarsonite ld: white crystals, m.p. 35-36 C (from acetonitrile);
yield 66%. IR (KBr), cm: 2916 (vs); 2848 (vs); 1736 (vs); 1726 (s); 1470 (s); 1180 (s); 1164 (s); 742 (s);
692 (s). H-NMR (CC14), 5, ppm: 0.90 (br s,6H, 2Me); 1.15-1.25 (m, 44H, 22CH2); 2.20 (br s, 6H, CH2As
+ 2CH2COO from myristoyl); 4.10 (m,2H, COOCH2); 5.30 (m, lH, COOCH); 7.15-7.60 (m,10H, 2Ph,
ArH). Rf 0.42 in CHCl3/petroleum ether 1:1, v/v; R 0.71 in Et20/petroleum ether 1:4, v/v. Analysis, found:
C, 65.5; H, 8.7; S, 7.8 %; C43H69OaAsS2 requires: C, 65.4; H, 8.7; S, 8.1%.
Di-(2-naphthyl) rac-2,3-dimyristoyloxypropyldithioarsonite le" white crystals, m.p. 132-135 C (from
petroleum ether); yield of 54%. IR (KBr), cm: 2920 (m); 2850 (m); 1740 (m); 814 (s); 738 (s); 478 (s); IH-
NMR (CC14), , ppm: 0.90 (br s,6H, 2Me); 1.14-1.25 (m, 44H, 22CH2); 2.20 (br s, 6H, CH2As +
2CH2COO from mirystoyl); 4.10 (m,2H, COOCH); 5.30 (m, lH, COOCH); 7.02-7.740 (m,14H, 2C0H7,
ArH). R 0.47 in CHC13/petroleum ether 1:1, v/v; Rr 0.55 in EtO/petroleum ether 1:4, v/v. Analysis, found:
C, 68.5; H, 8.1; S, 7.3 %; CsH7OnAsS2 requires: C, 68.9; H, 8.2; S, 7.2%.
Results hnd Discussion
Inhibition data with the newly synthesized racemic thioarsenites la-e are shown in Table I, against
the two red cell isozymes CA I and CA II.
As seen from data of Table I, the "lipothioarsenites" 1 (this name was coined due to the structural
-3.6 37 similarity of such derivatives to arsonolipids 2, for whi6h CA II inhibitory properties were previously
reported 7) are able to inhibit both CA I and CA II only when in the-As(SR)2 moiety there are COOH
functionalities. Compounds substituted with aromatic groups (ld,e) are practically inactive (inhibition
observed with these compounds at concentrations higher than mM (data not shown) may be due to a non-
specific hydrophobic interaction between the enzyme and the inhibitor).
For the three active derivatives, la-c, the following observations can be made: (i) inhibitory power
is greater when R moieties of the -As(SR)2 group are smaller (with small differences of activity between the
mercaptoacetic acid derivative la and the cysteine derivative lb, but with a considerable loss of activity for
the much bulkier glutathione derivative lc); (ii) derivatives la-c act as better inhibitors ofCA I compared to
CA II, as observed for anion inhibitors but not for sulfonamides.
2’9"38 It is also obvious that in order for a
lipothioarsenite to act as inhibitor, a coordinating group must be present in its molecule, which in this case
is probably the carboxyl moiety. However, the acylated (myristoylated in our case) propanediol moiety of
derivatives la-c is also important for inhibition, since as seen from Table II, mercaptoacetic acid, L-cysteine
or glutathione (the three thiols from which the thioarsenites were prepared) do not possess inhibitory effects
at all.
Table I: CA I and II inhibition with arsenic derivatives I and 2 at 25C. The concentration of 4-nitrophenyl
acetate was 4.10
.4 M (in acetonitrile), 10 mM Tris sulfate buffer, pH 7.0 (It 0.1 -K2SO4); [CA I] 13.0
M; [CA II] 4.9 I.tM.
n-C13H27COO,,,1
n-C13H27COO1
=--As(SR)2
n-C13H27COO-1
n-C13H27COO"1
=,,-AsO3H2
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ICso (M)
CA I CA II
la CH2COOH
Ib CH2CH(NH2)COOH
1c CH2CHNHCOCH2CH(NH2)COOH
CONHCH2COOH
ld Ph
I e 2-naphthyl
2 n-Ct3H27
11 42
15 49
152 230
>1000 >1000
>1000 >1000
16 0.15
Cysteine derivative; Glutathione derivative; CFrom ref. 17.
Table II: CA I and Ii activation by thiols 3-5 in concentration of 10 [tM. Other conditions were as described
in Table I.
Compound % CA Activity
CA I CA II
Mercaptoacetic acid, 3 113.4 115.3
L-Cysteine, 4 122.3 121.5
Glutathione, 5 139.7 142.5
Enzyme activity in the absence of activator is taken as 100%.
Further information regarding the interaction of the active inhibitors with the enzyme was obtained
by investigating the electronic spectrum of Co(II)-substituted CA II, and its adducts with inhibitors of type
39 41 41 la-c. It was proved earlier that inhibitors containing carboxylate moieties, such as formate, acetate,
oxalate,
4’ or benzoate
9 directly bind the metal ion in Co(II)CA. Co(II) is in pentaco-ordinated geometry in
such adducts, with the three histidine residues of the enzyme, a water molecule and the carboxylate moiety of
the inhibitor as ligands.
9’394’ This has been recently confirmed by the report of the X-ray structure of the
formate adduct of CA II.
42 Recently, other carboxylate inhibitors were reported, such as the non-steroidal
antiinflammatory drugs ibuprofen 6 and flurbiprofen 7,
43 or the positively-charged derivatives of p-
;14 aminosalicyhc acid 8. It was proposed that such inhibitors directly bind to the metal ion through the
negatively-charged oxygen atoms of the carboxylate moieties.
43’44
R2
6: RI=/-Bu; R2=H
7: Rl=ph; R2=F
R OOH
=R BF4"
8: R=alkyl or aryl
In Table Ill electronic spectra of the adducts of derivatives la-d as well as some carboxylate anions
with Co(II)CA II are reported, which show that inhibitors la-c interact with the metal ion by means of their
COO group(s), whereas the inactive derivative ld does not alter the spectrum of the cobalt-enzyme. The
spectra of the three derivatives are quite similar with those of the benzoate or acetate adducts previously
reported.
9’45’46’5 It should also be mentioned that adducts of Co(II)CA II with the thioarsenites 1 are not very
stable. After 15 30 min these solutions showed the typical spectrum of Co(III)CA,
51 (data not shown)
proving that oxidation of the metal ion occurred.
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Table III: Electronic spectra of the adducts of Co(II)CA II with inhibitors 1 and carboxylate anions, at pH 7.5
and 0.2mM enzyme concentration.
Adduct pH Band position ,nm (molar absorptivity [M
1 cml])
pure enzyme 6.0
pure enzyme 7.6
acetate 7.6
benzoate 7.6
la 7.6
lb 7.6
lc 7.6
ld 7.6
520 (180); 550 (250); 616.5 (135); 640 (100)
520 (240); 550 (310); 616.5 (220); 640 (200)
472 (100); 515 sh (80); 555 (110); 709 sh (10)
480 sh (110); 507 sh (170); 555 (220); 591 sh (160)
475 (100); 510 sh (110); 555 (180); 596 sh (150)
477 (90); 510 sh (120); 555 (210); 595 sh (150)
482 (100); 507 sh (110); 555 (200); 600 sh (170)
519 (240); 550 (310); 616.5 (220); 640 (200)
In conclusion, lipothioarsenites of type 1 possessing at least one COOH group act as inhibitors of
isozyme CA I and II. They bind to the Co(II) ion in the cobalt-substituted enzyme in a manner similar to the
carboxylate inhibitors, such as acetate or benzoate, the Co(II) having a trigonal-bipyramidal geometry.
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